Mandate

Biovitrum AB acquires the pharmaceutical company Arexis AB

October 03, 2005

Biovitrum, a Swedish biotech company, acquires Arexis, a privately owned Swedish biotech and pharmaceuticals company, for an undisclosed consideration, from 3i Group Plc, Beijer Investors, Industrifonden, InnovationsKapital, and SEB Företagsinvest.

Vinge acted for Biovitrum AB.
Michael Wigge (responsible partner)
Niclas Bergström (associate)

The Scope of Work According to AB 04

One of the most important parts of a construction agreement is the part where the scope of work is defined. There is a major difference between finding scope of work issues early in a construction project, instead of later during the execution phase.
May 04, 2021

A shift in EU merger control policy and practice could affect deal certainty and create opportunities for complainants

The European Commission is expanding its control of mergers and acquisitions within the existing legal framework, allowing national authorities to refer a transaction they do not have jurisdiction over for review in Brussels.
April 26, 2021

Vinge awarded Sweden Law Firm of the Year 2021 by Chambers & Partners

The award, Chambers Europe Award for Excellence – Sweden Law Firm of the Year 2021, is one of the foremost awards a Swedish law firm can receive. Vinge has previously received the award on four occasions.
April 23, 2021